Telik, Inc.

Terrapin Technologies, Inc.

Other

Sanwa Kagaku Kenkyusho Co., Ltd.

Triad Therapeutics, Inc.

Hugo O Villar

Lawrence M Kauvar

Edgardo Laborde

Louise Robinson

Kouji Matsushima

Yoshiro Ishiwata

Yukiharu Matsumoto

Shoji Yokochi

Fanying Meng

Brian T Peterson

Hideaki Inagaki

Steven E Anuskiewicz

Takahito Jomori

Takuji Kakigami

Richard Sportsman

Wayne R Spevak

Steven R Schow

Robert T Lum

Michael R Kozlowski

John W Patterson

Matthew H Lyttle

Dorit Ron

Wenli Ma

Mark R Hansen

Apparao Satyam

Mitsuaki Takeuchi

Nicki Vasquez

Anna Voronova

Robert W Macsata

Thomas Redelmeier

Micheal M Wick

Gene Napolitano

Kunihisa Baba

Katsumasa Tanaka

Masayuki Okamoto

Takashi Nakamura

Atsushi Miyachi

Richard Kho

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

Antagonists of MCP-1 function and methods of use thereof

Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formulawherein Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.

Nonpeptide insulin receptor agonists

Pharmaceutical compositions and methods of using them. Lipid formulations of a glutathione analog and methods of manufacturing them. Their use to stimulate hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a chemotherapeutic agent or irradiation, or to potentiate the effect of a chemotherapeutic agent.

Therapeutic compositions containing glutathione analogs

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formulawherein

Compounds of formula A and formula B:and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The compounds are antagonists of MCP-1 function, and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis, and in the prevention and treatment of allergic hypersensitivity disorders.

Antagonist of MCP-1 function, and compositions and methods of use thereof

Compounds, compositions, and methods for inhibiting the glycine transporterand for inhibiting glycine transporter mediated neuronal activity. These compounds are particularly useful for treating diseases of the nerve and muscle, including psychoses, pain, epilepsy, neurodegenerative diseases, stroke, head trauma, multiple sclerosis and the like, and of muscle disorders, including diseases or conditions associated with increased muscle contraction, such as spasticity and myoclonus. In addition, the compounds may be used to discover other agents with improved activity in assays in which the compounds of the invention are active.

Heterocyclic inhibitors of glycine transporter 2

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

The invention provides a method for separating two or more subsets of polypeptides within a set of polypeptides. The method includes the steps of: (a) determining a sequence comparison signature for each amino acid sequence in a set of amino acid sequences, wherein the sequence comparison signature includes pairwise comparison scores for the amino acid sequence compared to each of the other amino acid sequences in the set; (b) constructing a distance arrangement including the sequence comparison signatures related according to the distance between each of the sequence comparison signatures; and (c) identifying a first and second cluster of sequence comparison signatures in the distance arrangement, wherein the first cluster includes sequence comparison signatures for polypeptides having a similar protein fold or biological function, the protein fold or function being different compared to a protein fold or function of polypeptides having sequence comparison signatures in the second cluster.

Methods for determining polypeptide structure, function or pharmacophore from comparison of polypeptide sequences

Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and pharmaceutical compositions containing them, are useful in methods of treating autoimmune diseases, infectious diseases, and malignancies.

Substituted diarylureas as stimulators for Fas-mediated apoptosis

Methods for treating diseases associated with the activity of the insulin growth factor-1 receptor (IGF-1R), such as cancer, are provided. Methods for inhibiting cell growth and proliferation, especially of tumor cells, and promoting apoptosis are also provided. Each of these methods employs the use of a heteroaryl-aryl urea compound as an antagonist for IGF-1R.

Heteroaryl-aryl ureas as IGF-1 receptor antagonists

Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula

Growing community of inventors

La Jolla, CA, United States of America

Hugo O Villar